AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2666282 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic endoscopic sclerotherapy
Number of subjects: 87
Study 2666282 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sclerotherapy)
Number of subjects: 87
Study 29487957 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel pins from metacarpal head through MCP joint to proximal phalanx
Number of subjects: 61
Study 29487957 — intervention group
Group type: COMPARATOR
Intervention: Cross pins from the base of the proximal phalanx
Number of subjects: 61
Study 29487957 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (parallel pins and cross pins)
Number of subjects: 61
Study 27369739 — intervention group
Group type: EXPERIMENTAL
Intervention: Extralevator abdominoperineal excision (ELAPE)
Number of subjects: 34
Study 27369739 — intervention group
Group type: COMPARATOR
Intervention: Non-extralevator abdominoperineal excision (non-ELAPE)
Number of subjects: 34
Study 25759106 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration with isotonic saline (1 ml/kg/h since the beginning of the procedure and for 24 hours after it)
Number of subjects: 408
Study 25759106 — intervention group
Group type: COMPARATOR
Intervention: No hydration (NS- group)
Number of subjects: 408
Study 25759106 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration with isotonic saline
Number of subjects: 408
Study 23843932 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated emails with the Wellbeing Course
Number of subjects: 257
Study 23843932 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellbeing Course without automated emails
Number of subjects: 257
Study 23843932 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 257
Study 21734179 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4AP) 5 mg 3 times daily
Number of subjects: 10
Study 21734179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19827525 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrone system evaluation in CCI patients
Number of subjects: 30
Study 16760508 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg/d)
Number of subjects: 0
Study 16760508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12915826 — intervention group
Group type: COMPARATOR
Intervention: CICU LOS quartile 1
Number of subjects: 155
Study 12915826 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital LOS quartile
Number of subjects: 155
Study 10486353 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg twice daily for 24 months
Number of subjects: 68
Study 10486353 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily for 24 months
Number of subjects: 68
Study 8614905 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% metallic mercury in petrolatum
Number of subjects: 60
Study 8614905 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% phenyl mercuric acetate in water
Number of subjects: 60
Study 8614905 — intervention group
Group type: COMPARATOR
Intervention: Saline or petrolatum (control)
Number of subjects: 60
Study 2006663 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics and methyldopa
Number of subjects: 691
Study 2006663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study 7168635 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term prophylaxis with a single intravenous dose of tobramycin and lincomycin
Number of subjects: 30
Study 7168635 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment (control group)
Number of subjects: 30
Study 31352415 — intervention group
Group type: EXPERIMENTAL
Intervention: Postextubation medical therapy (azithromycin 250 mg and budesonide 0.5 mg for 14 days)
Number of subjects: 0
Study 31352415 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 31352415 — intervention group
Group type: EXPERIMENTAL
Intervention: Postextubation medical therapy (azithromycin and inhaled budesonide)
Number of subjects: 0
Study 28069467 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of pantoprazole twice daily and diet changes for 3 months
Number of subjects: 44
Study 28069467 — intervention group
Group type: COMPARATOR
Intervention: Control group (asymptomatic subjects)
Number of subjects: 44
Study 28069467 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (pantoprazole and diet changes)
Number of subjects: 44
Study 26161926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study 26161926 — intervention group
Group type: COMPARATOR
Intervention: Watch-and-wait (placebo)
Number of subjects: 0
Study 22955246 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS‐MPH
Number of subjects: 215
Study 22955246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 21498312 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight-adapted CM injection protocol (0.9 mL CM (370 mg I/mL) per kg during 12 s resulting in a constant injection dose rate of 28 mg I/kg/s)
Number of subjects: 100
Study 21498312 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose CM injection protocol (65 mL CM (370 mg I/mL) at 5 mL/s)
Number of subjects: 100
Study 18184948 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0
Study 18184948 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine (active control)
Number of subjects: 0
Study 16831185 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) with partial thickness flap
Number of subjects: 15
Study 16831185 — intervention group
Group type: COMPARATOR
Intervention: Epithelial abrasion
Number of subjects: 15
Study 19761076 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens
Number of subjects: 0
Study 10925979 — intervention group
Group type: EXPERIMENTAL
Intervention: 500‐mg Rowasa (mesalamine) suppository
Number of subjects: 65
Study 10925979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 8923784 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen I: 400 mg of MST-16 combined with 25 mg of VP-16 administered daily
Number of subjects: 31
Study 8923784 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen II: 400 mg of MST-16 combined with 25 mg of VP-16 administered intermittently (3 days a week or every other day)
Number of subjects: 31
Study 1376177 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. polyimmune gammaglobulin (500 mg/kg) within 3 days of transplant with 250 mg/kg at weeks 1, 2, 4, and 6
Number of subjects: 0
Study 1376177 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study 1376177 — intervention group
Group type: EXPERIMENTAL
Intervention: Nashville/rabbit antithymocyte serum (N/R‐ATS)
Number of subjects: 0
Study 1376177 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal anti‐CD‐3 therapy
Number of subjects: 0
Study 6377851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections of 40 mg of mixed gangliosides for ALS for six months
Number of subjects: 40
Study 6377851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections of 40 mg of mixed gangliosides for diabetic neuropathy for three months
Number of subjects: 40
Study 30835650 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) at 30 Hz
Number of subjects: 59
Study 30835650 — intervention group
Group type: EXPERIMENTAL
Intervention: Static first position demi-plié
Number of subjects: 59
Study 29140142 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (0.09 g·kg‐1)
Number of subjects: 13
Study 29140142 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee (0.09 g·kg‐1)
Number of subjects: 13
Study 27680390 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise intervention
Number of subjects: 47
Study 23553186 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based information
Number of subjects: 1577
Study 23553186 — intervention group
Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 1577
Study 22676647 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic technique
Number of subjects: 38
Study 22676647 — intervention group
Group type: COMPARATOR
Intervention: Sham technique
Number of subjects: 38
Study 20386344 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 alone (transdermal E2 0.72 mg for 2 days)
Number of subjects: 20
Study 20386344 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + DNG (E2 0.72 mg + DNG 2 mg/d for 1 week)
Number of subjects: 20
Study 20386344 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + MPA (E2 0.72 mg + MPA 2.5 mg/d for 1 week)
Number of subjects: 20
Study 20386344 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study 18245699 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery grafting
Number of subjects: 124
Study 18245699 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary bypass
Number of subjects: 124
Study 18245699 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study 16345016 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug
Number of subjects: 0
Study 16345016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural psychotherapy
Number of subjects: 0
Study 16345016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14602753 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hGH (0.067 mg/kg.d)
Number of subjects: 11
Study 14602753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11199863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour resection
Number of subjects: 24
Study 11199863 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 24
Study 9408810 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/day or 1 mg/day
Number of subjects: 79
Study 8329024 — intervention group
Group type: EXPERIMENTAL
Intervention: CB0006 at 0.1 mg/kg
Number of subjects: 41
Study 8329024 — intervention group
Group type: EXPERIMENTAL
Intervention: CB0006 at 1 mg/kg
Number of subjects: 41
Study 8329024 — intervention group
Group type: EXPERIMENTAL
Intervention: CB0006 at 5 mg/kg
Number of subjects: 41
Study 8329024 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 children)
Number of subjects: 41
Study 4036826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole infusion (0.14 mg/kg/min for 4 minutes)
Number of subjects: 66
Study 4036826 — intervention group
Group type: COMPARATOR
Intervention: Exercise stress testing (EST)
Number of subjects: 66
Study 30803743 — intervention group
Group type: EXPERIMENTAL
Intervention: K-wire group (20 patients)
Number of subjects: 40
Study 30803743 — intervention group
Group type: COMPARATOR
Intervention: Plate group (20 patients)
Number of subjects: 40
Study 29538628 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaphor message (the body is a family)
Number of subjects: 168
Study 29538628 — intervention group
Group type: COMPARATOR
Intervention: No metaphor message
Number of subjects: 168
Study 27393268 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization
Number of subjects: 177
Study 27393268 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 177
Study 27393268 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization and Hysterectomy
Number of subjects: 177
Study 24814231 — intervention group
Group type: EXPERIMENTAL
Intervention: IN dexmedetomidine (1 μg/kg) with midazolam premedication
Number of subjects: 100
Study 24814231 — intervention group
Group type: EXPERIMENTAL
Intervention: IN fentanyl (2 μg/kg) with midazolam premedication
Number of subjects: 100
Study 24814231 — intervention group
Group type: EXPERIMENTAL
Intervention: IN dexmedetomidine (1 μg/kg) without premedication
Number of subjects: 100
Study 24814231 — intervention group
Group type: EXPERIMENTAL
Intervention: IN fentanyl (2 μg/kg) without premedication
Number of subjects: 100
Study 24814231 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 100
Study 22858558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 319
Study 19076177 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate/early loading of zygomatic implants
Number of subjects: 25
Study 19076177 — intervention group
Group type: COMPARATOR
Intervention: Regular implants
Number of subjects: 25
Study 19076177 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate/early loading protocol
Number of subjects: 25
Study 18441038 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (9 minutes of electrical stimulation on the dorsiflexor muscles and 15 minutes of inhibitory Bobath techniques)
Number of subjects: 40
Study 18441038 — intervention group
Group type: COMPARATOR
Intervention: Bobath techniques (15 minutes)
Number of subjects: 40
Study 18441038 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 40
Study 18441038 — intervention group
Group type: COMPARATOR
Intervention: Bobath techniques
Number of subjects: 40
Study 16160622 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (initial dose 2 mg/d, titrated to 5, 10, or 15 mg/d)
Number of subjects: 208
Study 16160622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 16160622 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 208
Study 12969190 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN TIW (5 MU thrice weekly for 8 weeks followed by 3 MU TIW for 40 weeks)
Number of subjects: 301
Study 12969190 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN QD (5 MU daily for 8 weeks followed by 3 MU QD for 16 weeks followed by 3 MU TIW for 24 weeks)
Number of subjects: 301
Study 12969190 — intervention group
Group type: COMPARATOR
Intervention: IFN TIW
Number of subjects: 301
Study 12969190 — intervention group
Group type: COMPARATOR
Intervention: IFN QD
Number of subjects: 301
Study 10397076 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA treatment (200 ml of BCAA-rich solution daily for 7 days)
Number of subjects: 11
Study 10397076 — intervention group
Group type: COMPARATOR
Intervention: Thyrotropin-releasing hormone (TRH; protirelin)
Number of subjects: 11
Study 10397076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8025461 — intervention group
Group type: EXPERIMENTAL
Intervention: Allen scores
Number of subjects: 231
Study 8025461 — intervention group
Group type: EXPERIMENTAL
Intervention: Siriraj scores
Number of subjects: 231
Study 2582726 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilting test
Number of subjects: 67
Study 2582726 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid baroreceptor stimulation by neck suction
Number of subjects: 67
Study 2582726 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged head-up tilting test (up to 1 hour)
Number of subjects: 67
Study 2582726 — intervention group
Group type: COMPARATOR
Intervention: Neck suction stimulation
Number of subjects: 67
Study 780407 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol at 400 mug per day for 4 weeks
Number of subjects: 93
Study 780407 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 93
Study 30802725 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dairy condition (4 servings a day of full-fat dairy products + regular diet)
Number of subjects: 60
Study 30802725 — intervention group
Group type: COMPARATOR
Intervention: No-dairy condition (plant-based food items + regular diet)
Number of subjects: 60
Study 30802725 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dairy condition
Number of subjects: 60
Study 30802725 — intervention group
Group type: COMPARATOR
Intervention: No-dairy condition
Number of subjects: 60
Study 28577584 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Computer-Assisted CIFFTA
Number of subjects: 80
Study 25700756 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon aortic valvuloplasty (BAV) within 30 days of randomization
Number of subjects: 179
Study 25700756 — intervention group
Group type: COMPARATOR
Intervention: No balloon aortic valvuloplasty (no BAV) within 30 days of randomization
Number of subjects: 179
Study 23777324 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac epolamine (DHEP) 1.3% medicated plaster
Number of subjects: 384
Study 23777324 — intervention group
Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 384
Study 19633850 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-88 delivered subcutaneously (SC) at doses ranging from 80 to 315 mg
Number of subjects: 76
Study 19633850 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-88 delivered subcutaneously (SC)
Number of subjects: 76
Study 18451646 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg once daily for 2 weeks
Number of subjects: 4372
Study 18451646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4372
Study 17239096 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 226
Study 17239096 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 226
Study 12792328 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Number of subjects: 48
Study 10993128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg)
Number of subjects: 166
Study 10993128 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (50-150 mg)
Number of subjects: 166
Study 9126791 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis G virus infection
Number of subjects: 117
Study 9126791 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C virus infection
Number of subjects: 117
Study 9126791 — intervention group
Group type: EXPERIMENTAL
Intervention: Coinfection with hepatitis C virus
Number of subjects: 117
Study 9126791 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C virus genotype 3a
Number of subjects: 117
Study 9126791 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C virus infection alone
Number of subjects: 117
Study 9126791 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis G virus positive patients
Number of subjects: 117
Study 9126791 — intervention group
Group type: EXPERIMENTAL
Intervention: Human immunodeficiency virus infection
Number of subjects: 117
Study 1541312 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release tablets once daily (o.m.)
Number of subjects: 16
Study 1541312 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release tablets twice daily (b.d.)
Number of subjects: 16
Study 1541312 — intervention group
Group type: COMPARATOR
Intervention: Plain tablets twice daily (b.d.)
Number of subjects: 16
Study 1541312 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 16
Study 1541312 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release tablets
Number of subjects: 16
Study 3157887 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoglycan
Number of subjects: 0
Study 3157887 — intervention group
Group type: COMPARATOR
Intervention: Capillary protective drug derived from rutin
Number of subjects: 0
Study 30846294 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional CO2 laser (AFCO2L) treatment
Number of subjects: 20
Study 30846294 — intervention group
Group type: COMPARATOR
Intervention: Standard scar care
Number of subjects: 20
Study 30296552 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl
Number of subjects: 51
Study 30296552 — intervention group
Group type: EXPERIMENTAL
Intervention: SilverSol/H2O2
Number of subjects: 51
Study 30296552 — intervention group
Group type: EXPERIMENTAL
Intervention: HYBENX
Number of subjects: 51
Study 30296552 — intervention group
Group type: EXPERIMENTAL
Intervention: QMix 2 in1
Number of subjects: 51
Study 30296552 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% NaOCl
Number of subjects: 51
Study 26811679 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone-ER (3-12 mg/day)
Number of subjects: 106
Study 26811679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 24977631 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOC-201
Number of subjects: 160
Study 24977631 — intervention group
Group type: COMPARATOR
Intervention: RBC transfusions
Number of subjects: 160
Study 22553980 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dronabinol
Number of subjects: 24
Study 22553980 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg dronabinol
Number of subjects: 24
Study 22553980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22553980 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (10 mg and 20 mg)
Number of subjects: 24
Study 20441572 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific cognitive behavioural therapy adapted for the elderly
Number of subjects: 0
Study 20441572 — intervention group
Group type: COMPARATOR
Intervention: Intensified treatment as usual
Number of subjects: 0
Study 20441572 — intervention group
Group type: COMPARATOR
Intervention: Guided self-help intervention
Number of subjects: 0
Study 20441572 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment conditions after 12 weeks
Number of subjects: 0
Study 20441572 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups at one-year follow-up
Number of subjects: 0
Study 17663093 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 0
Study 17663093 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 0
Study 16037751 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed micronized 17beta-estradiol
Number of subjects: 222
Study 16037751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 12139152 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vaccine prepared from insect saliva
Number of subjects: 0
Study 12139152 — intervention group
Group type: COMPARATOR
Intervention: Placebo (stable vaccine solvent)
Number of subjects: 0
Study 9923552 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT 300 mg/m2 per day plus LV 90 mg per day in three divided doses every 8 h for 28 days
Number of subjects: 19